Benzinga · Nov 5, 2026
Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $51
Guggenheim analyst Debjit Chattopadhyay maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $55 to $51.
NASDAQ · BEAM
Beam Therapeutics Inc.
Healthcare · Biotechnology
$25.15
Down-$1.87 (-6.92%)
Updated Nov 11, 2026, 2:30 PM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 2.79B
- P/E ratio
- -6.8
- Dividend yield
- 0.00%
- 52-week range
- $20.23 – $38.26
- Volume
- 3.12M
- Avg. volume
- 2.37M
Price performance · BEAM
BEAM price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 10, 2026
BEAM closed at $25.15 after 21 trading sessions, up 2.95% for the selected period.
- Last close
- $25.15
- Period change
- +2.95%
- Period low
- $23.47
- Period high
- $28.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 10, 2026 | $26.45 | $27.00 | $23.60 | $25.15 | 3.12M |
| Nov 9, 2026 | $26.79 | $27.39 | $25.955 | $27.02 | 1.29M |
| Nov 6, 2026 | $26.07 | $26.77 | $25.84 | $26.41 | 1.98M |
| Nov 5, 2026 | $27.365 | $27.48 | $24.88 | $25.87 | 2.99M |
| Nov 4, 2026 | $27.06 | $28.00 | $26.255 | $27.79 | 1.35M |
| Nov 3, 2026 | $26.26 | $27.20 | $25.99 | $26.33 | 1.43M |
| Nov 2, 2026 | $27.45 | $27.6699 | $25.79 | $25.87 | 1.45M |
| Oct 30, 2026 | $28.27 | $28.85 | $26.426 | $27.23 | 1.5M |
| Oct 29, 2026 | $28.72 | $29.7603 | $28.40 | $28.84 | 2M |
| Oct 28, 2026 | $24.61 | $28.86 | $24.50 | $28.78 | 5.01M |
| Oct 27, 2026 | $23.73 | $25.09 | $23.39 | $24.90 | 2.75M |
| Oct 26, 2026 | $24.00 | $24.11 | $23.65 | $23.79 | 1.4M |
| Oct 23, 2026 | $24.00 | $24.14 | $23.24 | $24.05 | 1.6M |
| Oct 22, 2026 | $24.385 | $25.29 | $24.00 | $24.56 | 1.38M |
| Oct 21, 2026 | $24.83 | $25.20 | $24.50 | $24.84 | 1.17M |
| Oct 20, 2026 | $24.00 | $25.06 | $23.61 | $24.93 | 1.48M |
| Oct 19, 2026 | $23.885 | $24.38 | $23.50 | $24.19 | 1.32M |
| Oct 16, 2026 | $24.56 | $24.56 | $23.16 | $23.47 | 1.65M |
| Oct 15, 2026 | $23.51 | $24.98 | $23.20 | $24.73 | 1.78M |
| Oct 14, 2026 | $24.13 | $24.26 | $23.28 | $23.65 | 1.66M |
| Oct 13, 2026 | $24.88 | $24.93 | $24.08 | $24.43 | 1.67M |
Latest BEAM news
The latest Smart Investors Daily articles mentioning BEAM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BEAM research
Overview
Company profile and research snapshot.
Company profile
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $38.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 5, 2026 | Guggenheim | Buy | — |
| Nov 4, 2026 | Wedbush | Outperform | — |
| Nov 4, 2026 | Canaccord Genuity | Buy | — |
| Oct 29, 2026 | Canaccord Genuity | Buy | — |
| Oct 28, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Nov 4, 2026
Canaccord Genuity Maintains Buy on Beam Therapeutics, Lowers Price Target to $78
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and lowers the price target from $79 to $78.
Yahoo · Nov 4, 2026
Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
BEACON Trial Results Selected for Official ASH Press Program Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026 CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base ed
Benzinga · Nov 4, 2026
Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
